{"product_id":"biolegend-317441","title":"Biolegend, 317441, Brilliant Violet 785™ anti-human CD4 Antibody, 25tests","description":"\u003cp\u003eCD4, also known as T4, is a 55 kD single-chain type I transmembrane glycoprotein expressed on most thymocytes, a subset of T cells, and monocytes\/macrophages. CD4, a member of the Ig superfamily, recognizes antigens associated with MHC class II molecules and participates in cell-cell interactions, thymic differentiation, and signal transduction. CD4 acts as a primary receptor for HIV, binding to HIV gp120. CD4 has also been shown to interact with IL-16.\u003cbr\u003e\n25tests\u003cbr\u003e\nVerified Reactivity: Human, Cynomolgus, Rhesus\u003cbr\u003e\nReported Reactivity: Chimpanzee\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Mouse\u003cbr\u003e\nImmunogen: Human peripheral T cells\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.\u003cbr\u003e\nConcentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780\/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.\u003cbr\u003e\nExcitation Laser: Violet Laser (405 nm)\u003cbr\u003e\nApplication Notes: The OKT4 antibody binds to the D3 domain of CD4 and does not block HIV binding. Additional reported applications (for the relevant formats) include: immunohistochemistry of frozen sections and blocking of T cell activation. This clone was tested in-house and does not work on formalin fixed paraffin-embedded (FFPE) tissue. The Ultra-LEAF™ purified antibody (Endotoxin \u0026lt; 0.01 EU\/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 317453 and 317454). In a small subset of individuals, the OKT4 clone does not bind to CD4 due to polymorphisms in CD4.9\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York. Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. 76:4061. Kmieciak M, et al. 2009. J. Transl. Med. 7:89. (FC) PubMed Cicin-Sain L, et al. 2010. J. Immunol. 184:6739. PubMed Rosenzweig M, et al. 2001. J. Med. Primatol. 30:36. Linder J, et al. 1987. Am. J. Pathol. 127:1. Boche D, et al. 1999. J. Neurovirol. 5:232. (IHC) Reinherz EL, et al. 1979. Proc. Natl. Acad. Sci. USA. 76:4061. (Immunogen) Lederman S, et al. 1991. Mol Immunol. 28:1171-81.\u003cbr\u003e\nProduct Citations: Sun C, et al. 2022. Nat Biomed Eng. 6:1004. PubMed Baharlou H, et al. 2022. Cell Rep. 40:111385. PubMed Ezeonwumelu IJ, et al. 2022. Int J Mol Sci. 23: . PubMed Du Bruyn E, et al. 2023. Nat Commun. 14:188. PubMed Kerns JS, et al. 2023. Bio Protoc. 13: . PubMed Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed Rivero-Hinojosa S, et al. 2021. Nat Commun. 12:6689. PubMed Vojtech L et al. 2019. PLoS One. 14(10):e0223901 . PubMed Schlicher L, et al. 2022. Int J Mol Sci. 23:. PubMed Lee PS, et al. 2022. MAbs. 14:2024642. PubMed Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed Tebas P, et al. 2021. J Clin Invest. 131:. PubMed Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed Rubio-Pérez C, et al. 2021. Nat Commun. 1503:12. PubMed Gurusamy D, et al. 2020. Cancer Cell. 37(6):818-833.e9. PubMed Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed Wang F, et al. 2021. Cell. 184(2):422-440.e17. PubMed Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed Serwas NK, et al. 2019. Nat Commun. 2.573611111. PubMed Lutter L, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1567. PubMed Bruggen JACV, et al. 2022. Blood Adv. :. PubMed Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed Zhang Q, et al. 2021. Sci Transl Med. 13:eabg6986. PubMed Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed Ruella M, et al. 2018. Nat Med. 24:1499. PubMed Moravcikova E, et al. 2018. Cytometry A. 93:894. PubMed Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed Wilson TL, et al. 2022. Cancer Discov. 12:2098. PubMed Adel–Patient K, et al. 2018. Clin Transl Allergy. 8:38. PubMed Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed Fierle JK, et al. 2021. Cell Reports Medicine. 2(8):100362. PubMed Darrah PA, et al. 2019. NPJ Vaccines. 4:21. PubMed Li L, et al. 2022. JCI Insight. 7:. PubMed\u003cbr\u003e\nRRID: AB_2561365 (BioLegend Cat. No. 317441) AB_2563242 (BioLegend Cat. No. 317442)\u003cbr\u003e\nStructure: Ig superfamily, type I transmembrane glycoprotein, 55 kD\u003cbr\u003e\nDistribution: T cell subset, majority of thymocytes, monocytes\/macrophages\u003cbr\u003e\nFunction: MHC class II co-receptor, lymphocyte adhesion, thymic differentiation, HIV receptor\u003cbr\u003e\nLigand\/Receptor: MHC class II molecules, HIV gp120, IL-16\u003cbr\u003e\nCell Type: Macrophages, Monocytes, T cells, Thymocytes, Tregs\u003cbr\u003e\nBiology Area: Immunology\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nAntigen References: 1. Center D, et al. 1996. Immunol. Today 17:476. 2. Gaubin M, et al. 1996. Eur. J. Clin. Chem. Clin. Biochem. 34:723.\u003cbr\u003e\nGene ID: 920\u003cbr\u003e\nUniProt: View information about CD4 on UniProt.org\u003cbr\u003e\nClone: OKT4\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nWorkshop: HCDM listed\u003cbr\u003e\nOther Names: T4\u003cbr\u003e\nIsotype: Mouse IgG2b, κ\u003cbr\u003e\nQ: I am unable to see expression of T cell markers such as CD3 and CD4 post activation.\u003cbr\u003e\nA: TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA\/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46866160844969,"sku":"317441","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/es\/products\/biolegend-317441","provider":"Iright","version":"1.0","type":"link"}